Re-Biopsies in Lung Cancer: When Benefits Are Explained, Patients Are Willing

According to a recent survey, most patients with lung cancer are willing to undergo additional biopsies if they have a grasp on how and why it could help them. 
BY LAUREN M. GREEN @OncNurseEditor
PUBLISHED: DECEMBER 22, 2016
Doctors may be surprised to know that their patients with lung cancer are more than willing to undergo additional biopsies when they understand the procedure may hold the key to expanding their treatment options.
 
Almost 82 percent of 340 lung cancer survivors participating in a national survey sponsored by the advocacy group LUNGevity said that they would consent to an additional biopsy if they knew it would help their healthcare team better match treatment to their specific cancer and personalize their care, versus just being told the test was “to look for mutations.”
 
This willingness to have an additional biopsy even held true among the nearly 50 percent of respondents who reported pain or complications from their initial biopsy, according to the survey. This group indicated an equal willingness to have another biopsy as those who didn’t have any issues with the first one.
 
The findings, reported at the recent annual conference of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria, grew out of a desire by LUNGevity to shed more light on anecdotal reports that physicians are reluctant to recommend additional biopsies because they assume that patients are likely to refuse.
 
Upal Basu-Roy, Ph.D., M.S., M.P.H., Director of Research and Policy at LUNGevity and an author on the study, said in an interview with CURE that during one of the group’s annual HOPE survivorship summits, patients had identified as an unmet need the failure to be advised of how a re-biopsy might open up additional treatment options to them.
 
“There was obviously a [communication] gap on both sides,” Basu-Roy said, and that provided the catalyst for the national survey, he added, “so we could ask patients directly.”
 
Basu-Roy acknowledged that biopsy can be difficult, and re-biopsies aren’t for every patient with lung cancer. Issues specific to lung biopsy include the patient’s general health status, the health and condition of the lung to have another biopsy and also the location of the cancer in the lung. “When you talk to a patient about biopsy, the first thing that comes to mind is that it can be a very stressful and painful process.”
 
Nevertheless, Basu-Roy said that he and his colleagues at LUNGevity were surprised to find overwhelming support for re-biopsy among the lung cancer survivors responding to this national survey. “We had these anecdotal stories from patients and doctors, but the big, striking, finding was that 8 out of 10 of the respondents were willing to undergo additional biopsy when the end benefit of matching the patient to a targeted therapy and more personalized treatment was explained to them.”  
 


Talk about this article with other patients, caregivers, and advocates in the Lung Cancer CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
Excitement Grows for Immunotherapy in Lung Cancer
A number of patients with lung cancer have benefitted from immunotherapy agents, and researchers in the field are excited that these treatments will continue to improve the field.
Personalized Treatment Needed for Advanced Lung Cancer
A more personalized approach is needed in treatment plans for patients with stage 3 non-small cell lung cancer (NSCLC), according to Thomas A. Hensing, M.D.
Tagrisso Approved for Frontline Lung Cancer Treatment
Tagrisso (osimertinib) was granted a Breakthrough Therapy Designation for the firstline treatment of patients who have metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).
Related Videos
Examining the Role of Stress in Lung Cancer
Syed Jafri, M.D., an assistant professor at the University of Texas McGovern School of Medicine, discusses the potential role that stress could play in lung cancer diagnoses.
Chris Draft on What Caregivers Should Know
NFL player and founder of the Chris Draft Family Foundation, Chris Draft, explains what caregivers need to know. 
What's Next in Immunotherapy?
Melanoma should not be considered to be in a "special category" that responds well to immunotherapy, according to Christian M. Capitini, M.D., assistant professor of Pediatrics at the University of Wisconsin.
x
//For side ad protocol